Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer
The purpose of this study is to evaluate the pathological complete response (pCR) rate in breast cancer patients treated with weekly paclitaxel liposome injection plus cisplatin preoperative regimen.
Breast Cancer
DRUG: paclitaxel liposome injection plus cisplatin
pathological complete remission (pCR) rate, after 4 months of preoperative treatment
Adverse Events as a Measure of Safety and Tolerability, 4 months during neoadjuvant therapy|clinical response rate, after 4 months of preoperative therapy
The purpose of this study is to evaluate the pathological complete response (pCR) rate in breast cancer patients treated with weekly paclitaxel liposome injection plus cisplatin preoperative regimen.